Edwards Lifesciences Is Poised For Solid Growth In 2025—Analyst Highlights TAVR Growth, Margin Expansion
Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...
Edwards Lifesciences upped to Buy at Stifel on TAVR growth
Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in 2025. Read more here.
Healio14h
CABG plus surgical AVR may suit certain older patients with aortic stenosis, CAD
CABG plus surgical aortic valve replacement for treatment of coronary disease and aortic stenosis was associated with better 5-year outcomes vs. PCI plus transcatheter aortic valve replacement in ...
Pharmabiz20h
Abbott introduces Navitor Vision in India, the next generation of heart valve technology designed to treat aortic stenosis
Abbott introduces Navitor Vision in India, the next generation of heart valve technology designed to treat aortic stenosis: Our Bureau, Mumbai Thursday, January 30, 2025, 15:15 Hr ...
Stifel raises Edwards Lifesciences stock to buy, target to $90
Stifel analysts upgraded Edwards Lifesciences (NYSE:EW) stock from Hold to Buy, citing potential growth acceleration in the Transcatheter Aortic Valve Replacement (TAVR) market. The firm also ...